Kadmon (KDMN) Stock Rating Reaffirmed by Piper Jaffray Companies
Kadmon (NYSE:KDMN)‘s stock had its “positive” rating restated by stock analysts at Piper Jaffray Companies in a research note issued on Tuesday, The Fly reports. They presently have a $9.00 price target on the stock, up from their previous price target of $7.00. Piper Jaffray Companies’ target price points to a potential upside of 95.23% from the company’s current price.
A number of other brokerages have also recently issued reports on KDMN. Zacks Investment Research raised shares of Kadmon from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Friday, January 12th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Kadmon in a report on Friday, November 17th. Finally, Jefferies Group increased their target price on shares of Kadmon to $16.00 and gave the company a “buy” rating in a report on Tuesday. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Kadmon presently has an average rating of “Hold” and an average target price of $10.21.
Shares of Kadmon (NYSE:KDMN) traded down $0.23 during trading on Tuesday, reaching $4.61. 2,654,495 shares of the company’s stock were exchanged, compared to its average volume of 1,205,268. Kadmon has a 12 month low of $2.05 and a 12 month high of $5.86. The stock has a market capitalization of $376.70, a PE ratio of -2.65 and a beta of 5.39.
WARNING: “Kadmon (KDMN) Stock Rating Reaffirmed by Piper Jaffray Companies” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://theolympiareport.com/2018/02/13/kadmon-kdmn-stock-rating-reaffirmed-by-piper-jaffray-companies.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.